Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib.
about
Charting the molecular network of the drug target Bcr-Ablc-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's diseaseSomatic DNA mutation analysis in targeted therapy of solid tumoursThe growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABLThe structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)X-ray crystal structure of bone marrow kinase in the x chromosome: a Tec family kinaseActive site profiling reveals coupling between domains in SRC-family kinasesDasatinib sensitizes KRAS mutant colorectal tumors to cetuximabRole of ABL family kinases in cancer: from leukaemia to solid tumoursOptimizing combination therapies with existing and future CML drugsA cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis.Tyrosine phosphorylation of WIP releases bound WASP and impairs podosome assembly in macrophagesA bead-based activity screen for small-molecule inhibitors of signal transduction in chronic myelogenous leukemia cells.Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinibDiscoidin domain receptors in disease.Inhibiting tyrosine phosphorylation of protein kinase Cδ (PKCδ) protects the salivary gland from radiation damageGlobal approaches to study protein-protein interactions among viruses and hostsThe SCLtTAxBCR-ABL transgenic mouse model closely reflects the differential effects of dasatinib on normal and malignant hematopoiesis in chronic phase-CML patientsDasatinib promotes Th1-type responses in granzyme B expressing T-cellsProteomic analysis shows synthetic oleanane triterpenoid binds to mTORA phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy.Methods for investigation of targeted kinase inhibitor therapy using chemical proteomics and phosphorylation profiling.Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315IPersistent inhibition of ABL tyrosine kinase causes enhanced apoptotic response to TRAIL and disrupts the pro-apoptotic effect of chloroquine.Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment.Improved angiostatic activity of dasatinib by modulation with hydrophobic chainsThe functional interplay between the t(9;22)-associated fusion proteins BCR/ABL and ABL/BCR in Philadelphia chromosome-positive acute lymphatic leukemiaInsulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance.The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells.Dysregulated Dscam levels act through Abelson tyrosine kinase to enlarge presynaptic arborsTyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance.Discoidin domain receptor tyrosine kinases: new players in cancer progressionABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell LinesPhosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors.Structure, regulation, signaling, and targeting of abl kinases in cancer.Novel Bruton's tyrosine kinase inhibitors currently in development.Mig6 is a sensor of EGF receptor inactivation that directly activates c-Abl to induce apoptosis during epithelial homeostasisRapid screening of novel agents for combination therapy in sarcomasBcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target.Chromophobe renal cell cancer--review of the literature and potential methods of treating metastatic disease.
P2860
Q24317707-A415FCC0-6F99-4321-A208-04A395F5A509Q24318974-83D219CB-C7DE-4C80-B152-46DD45E424FCQ26770324-14DC0992-68CE-482F-A362-59B9E641FFD3Q26866312-A4DBF819-C453-4903-938E-CF4102CCCCAAQ27653890-F229237A-AE67-43B0-B7B4-04F338475415Q27672770-66466C65-343D-4142-8034-6B1AFB9F8850Q27675080-D0A1BB90-2EEF-48C0-A8AD-0DB1FA39CCAFQ27851586-D3DA6E67-F10E-40B6-A105-4B355A0229A0Q28396643-C02C9442-8EAC-4C7C-9197-5DD4239BE3C4Q28475255-B715DB46-AD1B-4C62-93B8-F07725FD0D62Q30396736-9AAEB7A7-401C-468B-B6DA-BC62B292E24AQ30615575-43AEF7C0-7660-4FA0-8053-2C388F998ADCQ30981853-AF12A0C7-9AE7-4CA1-81C4-5BB6997BD66FQ33394812-3DE6EEB0-FAC1-4D2A-B585-BB1EA79FB506Q33605357-7A1B6B04-5D00-4D18-AFAA-11B8AE5C93B9Q33675916-26312171-9A61-4E5A-8B23-58C425F95AD9Q33703278-43226AD1-5015-4439-8266-A78603E40E31Q33798573-4B672221-09C3-4E5B-A378-F0F095C9B478Q33930605-02E69085-2A98-42CF-B472-9205B6F77CE0Q33983503-AF3D70AB-E89D-4BFB-A469-20E91BA2751FQ34194110-B9652D62-CD77-4ED0-81CA-BD2B84FBCD82Q34373301-D6B5E5B6-BFBA-4911-837B-8A7A885DE3ADQ34416737-FEF8ECF1-553E-4C34-A744-79B167CC5A00Q35023172-ED272C2E-FEC9-4E29-9755-44E1DC0AD0B6Q35063621-DC6BF4BB-EEC3-48E5-8C61-900627305691Q35178869-C2B276F5-0415-47BB-BBB8-C1E13975620FQ35547514-A6A59935-327C-4CCB-9CE3-02381FB59F9CQ35606589-B6436776-4A15-4C9C-8C35-053712250797Q35608944-668A7F77-CFC2-4466-BE81-F064BFFD072DQ35614540-71A9686A-A14A-4414-B235-D14E11ACBA92Q35946822-AA3AEBEE-0CB2-41A1-8664-2D390B666321Q35957518-85CBF543-638B-4DA7-9E7E-8E52DC81B8E4Q36106559-7257C904-B792-4DB5-8781-3872B62AF438Q36270666-BD97B7AD-2FDE-4E73-A590-85CEC603FF1CQ36443429-F151B73C-3EF7-4187-AEC0-79708ECC448AQ36673755-1B86DDC4-F89C-4CDB-AF8D-305AAE8DCCC7Q36852720-9E039626-B4CF-413F-B4D6-A5E185BDE2D5Q37298877-FC5B69BA-5849-4637-8012-A335B970D7F3Q37322437-BDCA17AB-42F8-42CC-A0DE-0C29DF26CC34Q37393870-FA5B3DB8-3CCC-4F85-B981-9ACAD938ABEB
P2860
Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib.
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib.
@ast
Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib.
@en
Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib.
@nl
type
label
Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib.
@ast
Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib.
@en
Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib.
@nl
prefLabel
Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib.
@ast
Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib.
@en
Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib.
@nl
P2860
P1433
P1476
Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib.
@en
P2093
P2860
P304
P356
10.1080/10428190801896103
P577
2008-04-01T00:00:00Z